The Cambridge, Mass.-based company entered an agreement with Wyeth Pharmaceuticals to buy back rights for the osteoarthritis product in the U.S. and five European countries. As a result, Genzyme will receive all end-user revenue in those territories for Synvisc (hylan G-F 20), the top-selling viscosupplementation product for pain due to osteoarthritis of the knee in the U.S. and Canada. (BioWorld Today)
California stem cell researchers might get a boost through the passage of Proposition 71, paving the way for $3 billion in state-backed funding, and biotech companies hope to feel some trickle-down effect. (BioWorld Today)
California stem cell researchers might get a boost through the passage of Proposition 71, paving the way for $3 billion in state-backed funding, and biotech companies hope to feel some trickle-down effect. (BioWorld Today)
Nastech Pharmaceutical Co. Inc.'s reformulated treatment for vitamin B-12 deficiency, Nascobal (cyanocobalamin) Nasal Spray, received an approvable letter from the FDA. (BioWorld Today)
Nastech Pharmaceutical Co. Inc.'s reformulated treatment for vitamin B-12 deficiency, Nascobal (cyanocobalamin) Nasal Spray, received an approvable letter from the FDA. (BioWorld Today)
Boosting hopes for a wider label than previously thought, Dendreon Corp. released final three-year follow-up data from a Phase III study of Provenge. (BioWorld Today)
